Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease Arabia trading limited / Arabmed Ongoing Dupixent 4 LPS18583 King Khalid University Hospital (Riyadh).
Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus Mirum Pharmaceuticals, Inc. / CTI Ongoing Maralixibat 3 MRX-802 King Faisal Specialist Hospital and Research Center (Riyadh).
A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE) Swedish Orphan Biovitrum AB/ Balsam Ongoing Efanesoctocog alfa 4 BIVV001005 King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR) Merck Sharp & Dohme KSA GmbH Ongoing Vericiguat 2 NCT0571408 King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
Immune Ablation Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation for The Treatment of Multiple Sclerosis: A Single-Arm Study King Faisal Specialist Hospital and Research Center (Riyadh) Ongoing Busulfan BOS / Cyclophosphamide/ Thymoglobulin 2 2251066 King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency (Harmony) Travere Therapeutics, Inc. / CTI Ongoing Pegtibatinase 3 TVTX-TVT058-301 King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Riyadh)
Randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4- related disease Sanofi / Arab Med Ongoing Rilzabrutinib 3 EFC17359 King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
DOMAIN Study: A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients with Diffuse Large B-Cell Lymphoma in the MEA Region. Astrazeneca Ongoing Acalabrutinib 4 D8220R0008 King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam)
Real-World Effectiveness and Safety Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Sacituzumab Govitecan in Second Line and Beyond in Kingdom of Saudi Arabia. Gilead Sciences / IQVIA Ongoing Sacituzumab Govitecan 4 GS-AE-979 King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam)
A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis. Sanofi / Arab Med Ongoing Frexalimab (SAR441344) 3 EFC17504 King Saud University Medical City (Riyadh)
View 11 - 20 From 816